Market Overview:
The global telomerase reverse transcriptase market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of cancer, technological advancements in telomerase reverse transcriptase therapies, and rising investments by key players in this market. Based on type, the global telomerase reverse transcriptase market is segmented into ASTVAC-1, ASTVAC-2, ETS-2300, and others. The ASTVAC-1 segment is expected to account for the largest share of the global telomerase reverse transcriptASE market in 2018. This segment is also projected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. Based on application, the global telomerASE reverse transcriptASE markeT is divided into lung cancer, ovarian cancer breast cancer,, and others.
Product Definition:
Telomerase Reverse Transcriptase is an enzyme that helps to maintain the length of telomeres, which are protective caps at the end of chromosomes. Telomerase Reverse Transcriptase is important because it helps to prevent cells from aging and dying.
ASTVAC-1:
ASTVAC-1 is a novel, non-integrating viral vector gene that codes for the structural protein of the virus. It is an RNA molecule that gets converted to DNA by reverse transcriptase activity and then integrates into the genome of infected cells. The process does not integrate into host DNA but rather forms a separate new strand of DNA next to the existing one in case if there are many genes present in a particular region.
ASTVAC-2:
ASTVAC-2 is a novel and specific reverse transcriptase enzyme that specifically catalyzes the conversion of telomeric DNA to RNA. It was discovered by researchers at the National Cancer Institute (NCI) in NIH, USA. The enzyme activity has been demonstrated for both human tissues and cells with high efficiency as compared to other enzymes including Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) enzyme which is used for amplification of cDNA from RNA/DNA hybrid samples.
Application Insights:
Based on the application, the market is segmented into lung cancer, ovarian cancer, breast cancer, and others. Lung cancer was estimated to be the largest application segment in 2017 owing to high usage of telomerase reverse transcriptase for treatment of different types of lung cancers. Increasing cases of lung and bronchus cancers across the globe are also expected to contribute towards large growth during forecast years.
Ovarian Cancer is anticipated to be one of fastest growing segments during forecast years due largely on increasing number ovary tumors globally which has led researchers & manufacturers focus on development & commercialization efforts for telomerase-based therapeutics. Telomerase activity has been proved effective against some types ductal carcinoma (DCD) as well as serous carcinoma (SCC).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, increased funding for research and development activities, and high prevalence of telomerase mutations that lead to accelerated aging. In addition, increasing R&D investment by companies is anticipated to drive regional growth over the forecast period. For instance, in May 2018, Pfizer Inc., a U.S.
Asia Pacific region is expected to witness lucrative growth during the forecast period owing to rising disposable income coupled with growing awareness about early diagnosis among patients leading towards higher adoption rate of novel therapeutics resulting in faster revenue generation from sales & distribution channels thus propelling regional demand over the forecast period.
Growth Factors:
- Increasing geriatric population: The global geriatric population is increasing at a rapid pace. This is expected to drive the demand for telomerase reverse transcriptase products in the coming years.
- Growing awareness about telomerase reverse transcriptase products: There is growing awareness about the benefits of telomerase reverse transcriptase products among consumers worldwide. This is likely to boost demand for these products in the near future.
- Rising prevalence of age-related diseases: The prevalence of age-related diseases such as cancer, Alzheimer’s disease, and heart disease is on the rise globally. This is expected to create a high demand for telomerase reverse transcriptases in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Telomerase Reverse Transcriptase Market Research Report
By Type
ASTVAC-1, ASTVAC-2, ETS-2300, Others
By Application
Lung Cancer, Ovarian Cancer, Breast Cancer, Others
By Companies
Argos Therapeutics Inc, Asterias Biotherapeutics Inc, e-Therapeutics Plc, F. Hoffmann-La Roche Ltd, Inovio Pharmaceuticals Inc, Invectys SA, Johnson & Johnson, Komipharm International Co Ltd, Mediolanum farmaceutici SpA, Telocyte LLC, Argos Therapeutics Inc, Ultimovacs AS, Vaxon Biotech
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
223
Number of Tables & Figures
157
Customization Available
Yes, the report can be customized as per your need.
Global Telomerase Reverse Transcriptase Market Report Segments:
The global Telomerase Reverse Transcriptase market is segmented on the basis of:
Types
ASTVAC-1, ASTVAC-2, ETS-2300, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Lung Cancer, Ovarian Cancer, Breast Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Argos Therapeutics Inc
- Asterias Biotherapeutics Inc
- e-Therapeutics Plc
- F. Hoffmann-La Roche Ltd
- Inovio Pharmaceuticals Inc
- Invectys SA
- Johnson & Johnson
- Komipharm International Co Ltd
- Mediolanum farmaceutici SpA
- Telocyte LLC
- Argos Therapeutics Inc
- Ultimovacs AS
- Vaxon Biotech
Highlights of The Telomerase Reverse Transcriptase Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ASTVAC-1
- ASTVAC-2
- ETS-2300
- Others
- By Application:
- Lung Cancer
- Ovarian Cancer
- Breast Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Telomerase Reverse Transcriptase Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Telomerase reverse transcriptase is a protein that helps to maintain the length of telomeres. Telomeres are protective caps at the end of chromosomes that protect DNA from being damaged. Telomerase reverse transcriptase helps to copy telomeric DNA back into regular chromosomal DNA, which can keep the telomere length stable.
Some of the key players operating in the telomerase reverse transcriptase market are Argos Therapeutics Inc, Asterias Biotherapeutics Inc, e-Therapeutics Plc, F. Hoffmann-La Roche Ltd, Inovio Pharmaceuticals Inc, Invectys SA, Johnson & Johnson, Komipharm International Co Ltd, Mediolanum farmaceutici SpA, Telocyte LLC, Argos Therapeutics Inc, Ultimovacs AS, Vaxon Biotech.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Telomerase Reverse Transcriptase Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Telomerase Reverse Transcriptase Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Telomerase Reverse Transcriptase Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Telomerase Reverse Transcriptase Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Telomerase Reverse Transcriptase Market Size & Forecast, 2020-2028 4.5.1 Telomerase Reverse Transcriptase Market Size and Y-o-Y Growth 4.5.2 Telomerase Reverse Transcriptase Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 ASTVAC-1
5.2.2 ASTVAC-2
5.2.3 ETS-2300
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Lung Cancer
6.2.2 Ovarian Cancer
6.2.3 Breast Cancer
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Telomerase Reverse Transcriptase Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Telomerase Reverse Transcriptase Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 ASTVAC-1
9.6.2 ASTVAC-2
9.6.3 ETS-2300
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Lung Cancer
9.10.2 Ovarian Cancer
9.10.3 Breast Cancer
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 ASTVAC-1
10.6.2 ASTVAC-2
10.6.3 ETS-2300
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Lung Cancer
10.10.2 Ovarian Cancer
10.10.3 Breast Cancer
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 ASTVAC-1
11.6.2 ASTVAC-2
11.6.3 ETS-2300
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Lung Cancer
11.10.2 Ovarian Cancer
11.10.3 Breast Cancer
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 ASTVAC-1
12.6.2 ASTVAC-2
12.6.3 ETS-2300
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Lung Cancer
12.10.2 Ovarian Cancer
12.10.3 Breast Cancer
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 ASTVAC-1
13.6.2 ASTVAC-2
13.6.3 ETS-2300
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Lung Cancer
13.10.2 Ovarian Cancer
13.10.3 Breast Cancer
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Telomerase Reverse Transcriptase Market: Competitive Dashboard
14.2 Global Telomerase Reverse Transcriptase Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Argos Therapeutics Inc
14.3.2 Asterias Biotherapeutics Inc
14.3.3 e-Therapeutics Plc
14.3.4 F. Hoffmann-La Roche Ltd
14.3.5 Inovio Pharmaceuticals Inc
14.3.6 Invectys SA
14.3.7 Johnson & Johnson
14.3.8 Komipharm International Co Ltd
14.3.9 Mediolanum farmaceutici SpA
14.3.10 Telocyte LLC
14.3.11 Argos Therapeutics Inc
14.3.12 Ultimovacs AS
14.3.13 Vaxon Biotech